Popular Articles

Vermont Legislature Passes Law Regulating All Drug/Device Company Marketing, Requiring Disclosure Of Gifts To Doctors
The Vermont Legislature has passed legislation (S 48) that bans nearly all gifts from pharmaceutical and medical device companies to health care providers, administrators and facilities in the state, the New York Times reports. The legislation specifically would prohibit drug and device makers from giving providers no-cost meals. Vermont"s legislation would go further than similar laws in other states like Massachusetts and Minnesota by requiring drug and medical device manufacturers who give gifts to health providers to publicly disclose recipients" names and dollar amounts of payments and gifts. The measure would not require manufacturers to disclose payments for clinical research of products undergoing FDA review, the Times reports. The legislation also would eliminate a loophole that allows manufacturers to conceal certain expenses by claiming them as trade secrets. In a recent report, the Vermont Office of the Attorney General said that medical product makers spent about $2.9 million on promotional efforts to the state"s health care providers in fiscal year 2008 and that nearly half of the state"s 4,573 licensed providers had received some type of incentive from drugmakers in the same year. The report, which was developed prior to passage of the new legislation, offers only aggregate data, as 83% of the manufacturer-declared payments were deemed to be trade secrets, the Times reports.Gov. Jim Douglas (R) is expected to sign the law, which would take effect July 1. Several state medical groups -- including the Vermont Association for Mental Health and the Vermont Medical Society -- have indicated support for the legislation.Marjorie Powell, a senior lawyer for the Pharmaceutical Research and Manufacturers of America, said the requirements under the new law appear redundant with new voluntary guidelines the group has issued on physician gifting practices. She said, "We think this is unnecessary, and it is not going to improve patient care," adding, "It makes it onerous not only for the company but also for the physician in Vermont, because this is going to be on a Web site" (Singer, New York Times, 5/20).
diet pills Prezzi dentisti croazia
SPECT MPI With Cardiolite(R) Used In BARI 2D Study To Evaluate Type 2 Diabetes And Coronary Artery Disease Treatment Strategies
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announced today that the company"s leading imaging agent, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), was used in a recently completed five-year study examining appropriate treatment regimens for patients with type 2 diabetes and coronary artery disease. The results of this study, known as The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D), will be presented by the University of Pittsburgh Graduate School of Public Health at a special symposium on Sunday, June 7, 2009, from 4:15 p.m. - 5:15 p.m. (CT) at the American Diabetes Association 69th Scientific Sessions in New Orleans.
News of the day
Watson Pharmaceuticals Receives A Complete Response Letter For Its 24-Week Formulation Of TRELSTAR(R) (triptorelin Pamoate) NDA From US FDA
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation of TRELSTAR(R) for the palliative treatment of advanced prostate cancer. The TRELSTAR(R) NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies.
Endocrinology

318 Articles On The H1N1 Swine Flu Virus Available Online Free Of Charge On SpringerLink

Springer Science+Business Media is offering all journal articles which deal with the H1N1 virus, or swine flu, free of charge on its online information platform http://www.springerlink.com. The articles can be found by using the search term "H1N1." A total of 318 scientific articles will be available to print out or download from now until 31 December 2009. In June 2009, the World Health Organization raised the worldwide pandemic alert level to Phase 6 in response to the ongoing global spread of the H1N1 virus. A Phase 6 designation indicates that a global pandemic is underway. More than 70 countries are now reporting cases of human infection with H1N1 flu. Eric Merkel-Sobotta, Executive Vice President Corporate Communications of Springer Science+Business Media, said, "As a global scientific, technical and medical publisher, Springer plays a major role in the distribution of scientific information and access to knowledge and research. Therefore we are making all studies, published up to now on the H1N1 virus, freely available online on SpringerLink. By doing this, we hope to push forward scientific research on the causes, cures and other facets of this virus." Renate Bayaz Springer


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):